Business Overview We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. We have historically advanced early-stage product candidates and we are pursuing new product candidates and platforms to build a product pipeline based on our deep understanding of immunotherapies. Business Strategy Our strategy is to leverage our considerable industry experience, understanding of immunotherapies, and development expe...
Q2 FY2026 — expected 2026-07-20
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-04-15 | 2024-12-31 | 0001683168-25-002584 | EDGAR | 49K words |
| 2024-04-15 | 2023-12-31 | 0001683168-24-002402 | EDGAR | — |
| 2023-03-02 | 2022-12-31 | 0001683168-23-001237 | EDGAR | — |
| 2022-01-26 | 2021-12-31 | 0001683168-22-000466 | EDGAR | — |
| 2020-08-24 | 2020-05-31 | 0001683168-20-002849 | EDGAR | — |
| 2019-08-29 | 2019-05-31 | 0001683168-19-002782 | EDGAR | — |
| 2018-08-29 | 2018-05-31 | 0001683168-18-002555 | EDGAR | — |
| 2017-08-29 | 2017-05-31 | 0001683168-17-002239 | EDGAR | — |
| 2016-08-29 | 2016-05-31 | 0001019687-16-007390 | EDGAR | — |
| 2015-08-31 | 2015-05-31 | 0001019687-15-003312 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-19 | 2025-09-30 | 0001683168-25-008543 | EDGAR | 13K words |
| 2025-08-19 | 2025-06-30 | 0001683168-25-006318 | EDGAR | — |
| 2025-05-20 | 2025-03-31 | 0001683168-25-003880 | EDGAR | — |
| 2024-11-19 | 2024-09-30 | 0001683168-24-008258 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001683168-24-005676 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001683168-24-003375 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001683168-23-007588 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001683168-23-005245 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001683168-23-003253 | EDGAR | — |
| 2022-11-01 | 2022-09-30 | 0001683168-22-007181 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001683168-22-005321 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001683168-22-003373 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-01-02 | 0001683168-25-000009 | EDGAR | 1K words |
| 2024-07-25 | 0001683168-24-005057 | EDGAR | — |
| 2024-05-31 | 0001683168-24-003923 | EDGAR | — |
| 2024-05-21 | 0001683168-24-003732 | EDGAR | — |
| 2024-04-29 | 0001683168-24-002761 | EDGAR | — |
| 2024-04-19 | 0001683168-24-002534 | EDGAR | — |
| 2024-03-28 | 0001683168-24-001813 | EDGAR | — |
| 2023-06-26 | 0001683168-23-004424 | EDGAR | — |
| 2023-05-03 | 0001683168-23-002890 | EDGAR | — |
| 2022-07-12 | 0001683168-22-004893 | EDGAR | — |
246 total filings indexed. 214 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000836564 |
| Ticker | CPMV |
| Exchange | OTC |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CPMV (~200 tokens, structured JSON with cryptographic provenance)